NCT00163267

Mirror Trial - Follow-Up Management of Peripheral Arterial Intervention With Clopidogrel

Follow-up Management of Peripheral Arterial Intervention With Clopidogrel MIRROR-Study

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: University Hospital Tuebingen · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

The Mirror Study is a randomized, double-blinded mono-centre trial the access the periinterventinal and postinterventional administration of clopidogrel in patients with peripheral vascular disease.

Detailed description

Clopidogrel is approved for secondary prevention of atherosclerosis in patients with peripheral vascular disease. Currently there are no data about the amount of platelet activation during peripheral arterial intervention, the effect of clopidogrel on platelet adhesion and its clinical impact. Patients with chronic peripheral arterial disease receive placebo or clopidogrel before the intervention and for 6 months in follow-up. Platelet activation, the effect on macro-and microcirculation will be assessed as well as clinical endpoints.

Conditions

• Peripheral Vascular Diseases

Interventions

Type	Name	Description
DRUG	clopidogrel	Best endovascular treatment either with one or the other drug arm should be investigated

Timeline

• Start date: 2005-09-01
• Primary completion: 2009-12-01
• Completion: 2011-04-01
• First posted: 2005-09-13
• Last updated: 2011-08-09

Locations

1 site across 1 country: Germany